Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study.
Gottfried E. Konecny
No relevant relationships to disclose
Neil Finkler
No relevant relationships to disclose
Agustin Garcia
Consultant or Advisory Role - Novartis
Francesco Raspagliesi
No relevant relationships to disclose
Carolina Muriel Lopez
No relevant relationships to disclose
Michael McCollum
No relevant relationships to disclose
M Jesus Rubio
No relevant relationships to disclose
Matthew Squires
Employment or Leadership Position - Novartis
Nicoletta Pirotta
Employment or Leadership Position - Novartis
Allison Upalawanna
No relevant relationships to disclose
Alejandro Javier Yovine
Employment or Leadership Position - Novartis
Rodney Paul Rocconi
No relevant relationships to disclose